Head-To-Head Comparison: Agios Pharmaceuticals (AGIO) & Its Rivals

Agios Pharmaceuticals (NASDAQ: AGIO) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Agios Pharmaceuticals to related businesses based on the strength of its profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Insider and Institutional Ownership

93.8% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Agios Pharmaceuticals has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ rivals have a beta of 8.32, meaning that their average share price is 732% more volatile than the S&P 500.

Profitability

This table compares Agios Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals -506.39% -69.64% -43.12%
Agios Pharmaceuticals Competitors -5,234.19% -213.28% -38.69%

Valuation & Earnings

This table compares Agios Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Agios Pharmaceuticals $69.89 million -$198.47 million -9.54
Agios Pharmaceuticals Competitors $284.49 million $34.10 million 66.78

Agios Pharmaceuticals’ rivals have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations for Agios Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals 0 1 11 0 2.92
Agios Pharmaceuticals Competitors 888 3272 11767 235 2.70

Agios Pharmaceuticals currently has a consensus target price of $75.70, suggesting a potential upside of 26.55%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.12%. Given Agios Pharmaceuticals’ rivals higher possible upside, analysts plainly believe Agios Pharmaceuticals has less favorable growth aspects than its rivals.

Summary

Agios Pharmaceuticals rivals beat Agios Pharmaceuticals on 8 of the 13 factors compared.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

What are top analysts saying about Agios Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agios Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit